{"id":28337,"date":"2026-11-07T06:13:00","date_gmt":"2026-11-06T23:13:00","guid":{"rendered":"https:\/\/businessupdate.id\/?p=28337"},"modified":"2026-11-06T19:42:43","modified_gmt":"2026-11-06T12:42:43","slug":"bio-farma-paparkan-riset-vaksi-tb-berbasis-lipovaxin","status":"publish","type":"post","link":"https:\/\/businessupdate.id\/?p=28337","title":{"rendered":"Bio Farma Paparkan Riset Vaksi TB Berbasis Lipovaxin"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>BusinessUpdate &#8211;<\/strong> PT Bio Farma (Persero) memaparkan hasil riset kandidat vaksin tuberkulosis (TB) berbasis platform Lipovaxin yang dikembangkan bersama Lipotek asal Australia pada 40th Stop TB Partnership Board Meeting di Denpasar, Bali, Jumat (6\/11\/2026).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cSaat ini kami sedang mengembangkan vaksin TB generasi baru,\u201d ujar Direktur Riset dan Pengembangan Bio Farma, Dicky Mahardhika Taryono, dalam sesi TB Vaccines: Are We Ready? pada pertemuan tersebut.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Badan Pengawas Obat dan Makanan (BPOM) menyetujui pelaksanaan uji klinis fase 1 untuk kandidat tersebut. Uji ini dirancang untuk menilai keamanan dan respons imun pada peserta dewasa yang sehat.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Menurut Dicky, Bio Farma telah melakukan persiapan teknis dan manufaktur seiring dengan pengembangan kandidat. Ia berharap pengembangan dapat mencapai tahap lanjutan pada 2028 atau 2029, termasuk kemungkinan peningkatan skala produksi. Kemajuan ke tahap berikutnya bergantung pada hasil uji klinis dan pemenuhan persyaratan regulasi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dicky menekankan pentingnya kolaborasi lintas sektor agar pengembangan vaksin dapat mendukung upaya eliminasi TB. Organisasi Kesehatan Dunia (WHO) memperkirakan Indonesia menyumbang sekitar 10% dari jumlah orang yang menderita TB di dunia pada 2024, menjadikannya penyumbang terbesar kedua setelah India.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sementara itu, Direktur Utama Bio Farma, Shadiq Akasya menyoroti potensi M72\/AS01E, kandidat vaksin TB yang awalnya dikembangkan oleh GlaxoSmithKline (GSK). Kandidat tersebut telah melalui uji klinis fase 1 dan 2 dan kini masih menjalani uji fase 3 yang disponsori oleh Gates Medical Research Institute (Gates MRI).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cBagi Bio Farma, kemitraan internasional perlu memperkuat kemampuan industri di Indonesia agar kita lebih siap mendukung pasokan vaksin TB bagi masyarakat. Untuk kandidat M72, kami sedang menjajaki kerja sama dengan Serum Institute of India untuk melihat kemungkinan alih teknologi formulasi di dalam negeri,\u201d ujar Shadiq.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pada Juli 2026, Gates MRI mengumumkan kesepakatan dengan Serum Institute of India untuk menyiapkan produksi antigen M72. Pengumuman itu juga menyebut rencana untuk melibatkan produsen lokal di Indonesia dan Afrika Selatan dalam bagian tertentu dari rantai pasok.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Menurut Shadiq, keterjangkauan harga perlu dipertimbangkan sejak tahap perencanaan akses penyediaan vaksin bagi masyarakat. Ia menyebut program pemerintah dan jalur komersial sebagai pilihan penyediaan apabila vaksin kelak memperoleh izin edar. Skema program mengikuti kebijakan pemerintah. Jika vaksin dipasarkan melalui jalur komersial, biaya riset, investasi fasilitas, dan biaya operasional menjadi pertimbangan dalam menentukan harga.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Shadiq berharap persiapan industri dan koordinasi dengan regulator dapat mendukung evaluasi yang lebih efisien. Keputusan izin edar mengikuti penilaian BPOM terhadap data uji klinis dan persyaratan regulasi. Apabila vaksin memperoleh izin edar, persiapan tersebut diharapkan dapat membantu Bio Farma menyiapkan pasokan untuk masyarakat. (pa\/jh. Foto: Dok. Bio Farma)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BusinessUpdate &#8211; PT Bio Farma (Persero) memaparkan hasil riset kandidat vaksin tuberkulosis (TB) berbasis platform Lipovaxin yang dikembangkan bersama Lipotek asal Australia pada 40th Stop TB Partnership Board Meeting di Denpasar, Bali, Jumat (6\/11\/2026). \u201cSaat ini kami sedang mengembangkan vaksin TB generasi baru,\u201d ujar Direktur Riset dan Pengembangan Bio Farma, Dicky Mahardhika Taryono, dalam sesi [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":28338,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[50],"tags":[855,13323,13322,13321,465],"class_list":["post-28337","post","type-post","status-publish","format-standard","has-post-thumbnail","category-scien-tech","tag-bio-farma","tag-lipotex","tag-lipovaxin","tag-tuberkulosis","tag-vaksin"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.5.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Bio Farma Paparkan Riset Vaksi TB Berbasis Lipovaxin - Businessupdate.id<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/businessupdate.id\/?p=28337\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio Farma Paparkan Riset Vaksi TB Berbasis Lipovaxin - Businessupdate.id\" \/>\n<meta property=\"og:description\" content=\"BusinessUpdate &#8211; PT Bio Farma (Persero) memaparkan hasil riset kandidat vaksin tuberkulosis (TB) berbasis platform Lipovaxin yang dikembangkan bersama Lipotek asal Australia pada 40th Stop TB Partnership Board Meeting di Denpasar, Bali, Jumat (6\/11\/2026). \u201cSaat ini kami sedang mengembangkan vaksin TB generasi baru,\u201d ujar Direktur Riset dan Pengembangan Bio Farma, Dicky Mahardhika Taryono, dalam sesi [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/businessupdate.id\/?p=28337\" \/>\n<meta property=\"og:site_name\" content=\"Businessupdate.id\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=100088795961927\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-06T23:13:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-06T12:42:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/businessupdate.id\/wp-content\/uploads\/2026\/11\/vaksin-tbc-biofarma-HO-e1793968942235.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"740\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Premieri A\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@EnterpriseMse\" \/>\n<meta name=\"twitter:site\" content=\"@EnterpriseMse\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Premieri A\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/businessupdate.id\/?p=28337\",\"url\":\"https:\/\/businessupdate.id\/?p=28337\",\"name\":\"Bio Farma Paparkan Riset Vaksi TB Berbasis Lipovaxin - Businessupdate.id\",\"isPartOf\":{\"@id\":\"https:\/\/businessupdate.id\/#website\"},\"datePublished\":\"2026-11-06T23:13:00+00:00\",\"dateModified\":\"2026-11-06T12:42:43+00:00\",\"author\":{\"@id\":\"https:\/\/businessupdate.id\/#\/schema\/person\/39a407b879699c9dfc68b893045cd07e\"},\"breadcrumb\":{\"@id\":\"https:\/\/businessupdate.id\/?p=28337#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/businessupdate.id\/?p=28337\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/businessupdate.id\/?p=28337#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/businessupdate.id\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio Farma Paparkan Riset Vaksi TB Berbasis Lipovaxin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/businessupdate.id\/#website\",\"url\":\"https:\/\/businessupdate.id\/\",\"name\":\"Businessupdate.id\",\"description\":\" \",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/businessupdate.id\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/businessupdate.id\/#\/schema\/person\/39a407b879699c9dfc68b893045cd07e\",\"name\":\"Premieri A\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/businessupdate.id\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/6ef707773e9166331976e40c3975862c82a2bdf65aa2185282dd7c4be2a1c87e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/6ef707773e9166331976e40c3975862c82a2bdf65aa2185282dd7c4be2a1c87e?s=96&d=mm&r=g\",\"caption\":\"Premieri A\"},\"sameAs\":[\"http:\/\/businessupdate.id\"],\"url\":\"https:\/\/businessupdate.id\/?author=5\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bio Farma Paparkan Riset Vaksi TB Berbasis Lipovaxin - Businessupdate.id","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/businessupdate.id\/?p=28337","og_locale":"en_US","og_type":"article","og_title":"Bio Farma Paparkan Riset Vaksi TB Berbasis Lipovaxin - Businessupdate.id","og_description":"BusinessUpdate &#8211; PT Bio Farma (Persero) memaparkan hasil riset kandidat vaksin tuberkulosis (TB) berbasis platform Lipovaxin yang dikembangkan bersama Lipotek asal Australia pada 40th Stop TB Partnership Board Meeting di Denpasar, Bali, Jumat (6\/11\/2026). \u201cSaat ini kami sedang mengembangkan vaksin TB generasi baru,\u201d ujar Direktur Riset dan Pengembangan Bio Farma, Dicky Mahardhika Taryono, dalam sesi [&hellip;]","og_url":"https:\/\/businessupdate.id\/?p=28337","og_site_name":"Businessupdate.id","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=100088795961927","article_published_time":"2026-11-06T23:13:00+00:00","article_modified_time":"2026-11-06T12:42:43+00:00","og_image":[{"width":1200,"height":740,"url":"https:\/\/businessupdate.id\/wp-content\/uploads\/2026\/11\/vaksin-tbc-biofarma-HO-e1793968942235.webp","type":"image\/webp"}],"author":"Premieri A","twitter_card":"summary_large_image","twitter_creator":"@EnterpriseMse","twitter_site":"@EnterpriseMse","twitter_misc":{"Written by":"Premieri A","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/businessupdate.id\/?p=28337","url":"https:\/\/businessupdate.id\/?p=28337","name":"Bio Farma Paparkan Riset Vaksi TB Berbasis Lipovaxin - Businessupdate.id","isPartOf":{"@id":"https:\/\/businessupdate.id\/#website"},"datePublished":"2026-11-06T23:13:00+00:00","dateModified":"2026-11-06T12:42:43+00:00","author":{"@id":"https:\/\/businessupdate.id\/#\/schema\/person\/39a407b879699c9dfc68b893045cd07e"},"breadcrumb":{"@id":"https:\/\/businessupdate.id\/?p=28337#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/businessupdate.id\/?p=28337"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/businessupdate.id\/?p=28337#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/businessupdate.id\/"},{"@type":"ListItem","position":2,"name":"Bio Farma Paparkan Riset Vaksi TB Berbasis Lipovaxin"}]},{"@type":"WebSite","@id":"https:\/\/businessupdate.id\/#website","url":"https:\/\/businessupdate.id\/","name":"Businessupdate.id","description":" ","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/businessupdate.id\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/businessupdate.id\/#\/schema\/person\/39a407b879699c9dfc68b893045cd07e","name":"Premieri A","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/businessupdate.id\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/6ef707773e9166331976e40c3975862c82a2bdf65aa2185282dd7c4be2a1c87e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6ef707773e9166331976e40c3975862c82a2bdf65aa2185282dd7c4be2a1c87e?s=96&d=mm&r=g","caption":"Premieri A"},"sameAs":["http:\/\/businessupdate.id"],"url":"https:\/\/businessupdate.id\/?author=5"}]}},"_links":{"self":[{"href":"https:\/\/businessupdate.id\/index.php?rest_route=\/wp\/v2\/posts\/28337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/businessupdate.id\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/businessupdate.id\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/businessupdate.id\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/businessupdate.id\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=28337"}],"version-history":[{"count":1,"href":"https:\/\/businessupdate.id\/index.php?rest_route=\/wp\/v2\/posts\/28337\/revisions"}],"predecessor-version":[{"id":28339,"href":"https:\/\/businessupdate.id\/index.php?rest_route=\/wp\/v2\/posts\/28337\/revisions\/28339"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/businessupdate.id\/index.php?rest_route=\/wp\/v2\/media\/28338"}],"wp:attachment":[{"href":"https:\/\/businessupdate.id\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=28337"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/businessupdate.id\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=28337"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/businessupdate.id\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=28337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}